The incorporation of the fatty acids in fish and olive oil into the colonic mucosa of patients with inflammatory bowel disease was examined during 12 weeks' dietary supplementation with the oils, and the influence on colonic mucosal prostaglandin and thromboxane generation was measured. With a dietary supplement of 18 g fish oil daily, concentrations of the major polyunsaturated fatty acids in fish oil, eicosapentaenoic acid and docosahexaenoic acid, were significantly raised in mucosal lipids. The first time these were measured, after three weeks' supplementation, the mean increases in eicosapentaenoic and docosahexaenoic acid were seven fold and 1.5 fold respectively, and these increases were maintained during the 12 week study. Arachidonic acid values fell throughout the study and this reduction was significant at 12 weeks. Mucosal prostaglandin E2 (PGE2), thromboxane B2, and 6-keto prostaglandin F,,, synthesis were suppressed, and this reached significance (p<005) at three and 12 weeks for PGE2 and at 12 weeks for thromboxane B2.
synthesis were suppressed, and this reached significance (p<005) at three and 12 weeks for PGE2 and at 12 weeks for thromboxane B2. The predominant fatty acid in olive oil is oleic acid. Supplementation with 18 g /day resulted in a significant increase in oleic acid in colonic mucosa at 12 weeks (p<0.05) and a fall in stearic acid and docosahexaenoic acid; there was no significant change in eicosanoid synthesis. It is concluded that colonic lipids and prostaglandin and thromboxane synthesis can be readily altered by dietary supplementation with fish oil. The extent of incorporation of the fatty acids present in oils is dependent upon the individual fatty acid.
olised to arachidonic acid (C20:4) and hence to dienoic eicosanoids such as prostaglandin E2 (PGE2), thromboxane A2 (TxA2), and leukotriene C4 (LTC4). The predominant polyunsaturated fatty acids present in fish oils are eicosapentaenoic acid (C20:5) and docosahexaenoic acid (C22:6). C20:5, which is absent in vegetable oils, has been shown to be metabolised to a family of trienoic eicosanoids, for example, PGE3, TxA3, and also LTC5 which have subtly different biological properties to the dienoic eicosanoids and LTC4 derived from arachidonic acid. It is hypothesised that fish oils may reduce inflammation via the production of relatively larger amounts of 3 series prostaglandins and 5 series leukotrienes which possess reduced inflammatory potential. In addition, fish oils may inhibit the cyclo-oxygenase enzymes that form prostaglandins and thromboxane. '°T he synthesis of several eicosanoids is increased in inflammatory bowel disease and may be responsible for some of the pathophysiological features of the disease. Mucosal samples taken from patients with active disease have increased capacity to synthesis PGE2,' TxA2,2 13 and leukotrienes. ' In both groups, the protocol followed reduced steroids every three weeks if improvement in the patient's condition was maintained. At a dosage of greater than 20 mg per day, reduction was by 10 mg, and at a dosage of less than 20 mg, by 5mg.
Patients attended the clinic three, six, and 12 weeks after admission to the study for reassessment and colonoscopy. The monitor procedural losses. The supernatant was then extracted, and analysed for PGE2, TxB2, or 6-keto-PGF10 by radioimmunoassay as described by de la Hunt et al. 23 The eicosanoids were eluted from the octadecasilyl silica microcolumns with distilled diethyl ether (10 ml). The ether was evaporated to dryness under nitrogen at 30°C and the residue reconstituted in 3 ml 0.1 mol/l phosphate buffer (pH 7.5). The samples were stored at -20°C until analysed.
Procedural losses were assessed by monitoring the recoveries of added recovery isotope and values corrected for losses; PGE2 and PGF2a recoveries were mean (SD) 79 (6)% (n=25) and 89 (7)% (n=47) respectively. In previous studies using gastric mucosa, the recoveries of PGE2, PGF2a, 6-keto-PGFIa, and TxB2 were in the range 81-91% (n=10-48) and did not differ significantly from each other or from recoveries in the present study. The eicosanoids PGE2, 6-keto-PGF1a ( (9) 14-4 (3.6) (8) 10.0 (4.5) (5) 16-8 (4.3) (3) 6keto-F,,,-fishoil 13-1(3-2) (11) 6.6(1*5)(9) 7-8(1*6)(8) 7-7(1*9) (9) * p<05 Wilcoxon's rank test and refers to comparison with values at entry to the trial (0 weeks).
mucosal fatty acids. The main unsaturated fatty acids present were C18:1, C18:2, and C20:4 while the main saturated fatty acids present were palmitic acid (C16:0) and C18:0. Table I shows that fish oil consumption had a considerable effect on C20:5 and C22:6 values. After three weeks, C20:5 had increased sevenfold (p<0 01) and C22:6 almost doubled (p<0 01). The increases were maintained during the study period. In the olive oil group, there were no significant changes in C20:5 and C22:6. The range of C20:5 on admission was 0 14-07% and after three weeks it was 0.86-49%. These data suggest that compliance in taking the capsules was acceptable. The individual patient values for the ratio of C20:4/C20:5 are shown in Figure 2 . At entry to the study, the ratio of C20:4/C20:5 in 10 of the 11 patients in the fish oil group ranged from 14-1-420, but in one patient the ratio was 74-2.
In the olive oil group the ratio in eight out of nine patients was 14-2-39.0 but in one patient it was 92-1. There was no dietary or other understood reason for high C20:4/C20:5 ratios in these two patients. The ratio of C20:4/C20:5 fell precipitously in all but one patient and remained low during the 12 week study period. Dihomo-ylinolenic acid (C20:3) was also significantly reduced in the fish oil group at three weeks and six weeks. In the olive oil group there was no increase in the C18:1 values in the colonic mucosa until 12 weeks supplementation (p<005), despite the fact that the diet provided 13.9 g per day C18: 1 in olive oil. There was also a fall in C 18:0 and C22:6 after 12 weeks in patients taking olive oil. Table II shows the prostaglandin and thromboxane synthesis by mucosal specimens in both groups. On admission to the study (week 0) there was no significant difference in eicosanoid synthesis between the fish oil and olive oil groups. The fish oil diet resulted in a significant reduction in PGE2 synthesis at three weeks and 12 weeks, although the decline at six weeks did not reach significance. At In an animal model, where a large bowel inflammatory colitis was induced in rats by the administration of trinitrobenzene sulphonic acid, fish oil, but not olive oil, reduced the chronic severity of the lesions,9 although the severity of the initial injury produced was similar in the olive oil and fish oil groups.
The pharmacological effects offish oil are such that it might be expected to benefit inflammatory bowel disease. It causes a suppression of the production of many potentially damaging mediators that have been shown to be produced in excess within the colonic mucosal cells in these disorders. Interleukin-1,2627 TxB2,'2 '3 leukotrienes,'4 2X platelet activating factor,29 and prostaglandins" 0 are all produced in greater amounts compared with normal mucosa and Hawkey et al"3 have also shown that there is an increased ratio of thromboxane to PGI2 in the colonic mucosa in Crohn's disease. It is of importance that some mediators that are produced act synergistically but others are, in fact, antagonistic; for example, PGE2 has been shown to inhibit interleukin synthesis. Further studies should determine whether different fats and varied dosage schedules have the ability to modulate selectively the production of particular mediators and whether this can favourably influence inflammatory bowel disease.
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